Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 7/20 | 0.45 |
| ▸ | HTR2B | P41595 | 7/20 | 0.45 |
| ▸ | HTR2A | P28223 | 6/20 | 0.45 |
| ▸ | PNMT | P11086 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16518081 | 0.93 | KDM4E (0.46) | KDM4EHTR2CHTR2BHTR2APNMT | |
| SCHEMBL6191941 | 0.87 | HTR2C (0.51) | KDM4EHTR2CHTR2BHTR2APNMT | |
| Hydrochloric Acid SCHEMBL5102358 | 0.84 | KDM4E (0.46) | KDM4EHTR2CHTR2BHTR2APNMT | |
| SCHEMBL19705569 | 0.81 | HTR2C (0.46) | HTR2CHTR2BHTR2APNMTCYP1A2 | |
| Hydrochloric Acid SCHEMBL38653786 | 0.78 | HTR2C (0.44) | HTR2CHTR2BHTR2APNMTHTR6 | |
| SCHEMBL23962916 | 0.77 | HTR2C (0.46) | KDM4EHTR2CHTR2BHTR2APNMT | |
| SCHEMBL17227391 | 0.77 | HTR2C (0.48) | KDM4EHTR2CHTR2BHTR2APNMT | |
| SCHEMBL8411765 | 0.77 | HTR2A (0.46) | HTR2CHTR2BHTR2APNMTHTR6 | |
| SCHEMBL18524349 | 0.77 | HTR2C (0.41) | HTR2CHTR2BHTR2APNMT | |
| SCHEMBL16518020 | 0.76 | HTR2C (0.45) | HTR2CHTR2BHTR2APNMTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2794563-B1 | HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2017-02-22 | — | — | EP | disclosed |
| US-20070010526-A1 | Therapeutic isoquinoline compounds | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | disclosed |
| EP-1451172-A1 | THERAPEUTIC ISOQUINOLINE COMPOUNDS | AstraZeneca AB (SE) | 2004-09-01 | — | — | EP | disclosed |
| WO-2003037887-A1 | THERAPEUTIC ISOQUINOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010526-A1 | Therapeutic isoquinoline compounds | HTR1B, HTR1D, HTR1A | KDM4E 1824/4885HTR2C 7/4885HTR2B 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.